Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
CC transcript
|
|
CareDx, Inc. (CDNA)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/26/2023 |
8-K
| Quarterly results |
| 08/08/2023 |
8-K
| Quarterly results |
| 05/10/2023 |
8-K
| Quarterly results |
| 04/03/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 03/28/2023 |
8-K
| Quarterly results |
| 02/27/2023 |
8-K
| Investor presentation, Quarterly results |
| 01/09/2023 |
8-K
| Investor presentation|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"CareDx Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2022 BRISBANE, Calif., January 9, 2023— CareDx, Inc. — The Transplant Company ™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers - today reported preliminary financial results for the fourth quarter and full year ended December 31, 2022. Fourth Quarter Highlights",
"Corporate Presentation of CareDx, Inc., dated January 2023" |
|
| 12/06/2022 |
8-K
| Quarterly results |
| 11/23/2022 |
8-K
| Quarterly results |
| 11/03/2022 |
8-K
| Quarterly results |
| 09/07/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 09/01/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/04/2022 |
8-K
| Quarterly results |
| 06/17/2022 |
8-K
| Quarterly results |
| 05/23/2022 |
8-K
| Quarterly results |
| 05/05/2022 |
8-K
| Quarterly results |
| 02/24/2022 |
8-K
| Quarterly results |
| 01/10/2022 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 01/05/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 11/10/2021 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 11/01/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"CareDx Completes Orderly Management Transition SOUTH SAN FRANCISCO, Calif., November 1, 2021 - CareDx, Inc. , a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that the company has completed its transition from Peter Maag, PhD, to Reginald Seeto, MBBS, as Chief Executive Officer. Concurrent with the appointment of Dr. Seeto as President and Chief Executive Officer of CareDx in November 2020, Dr. Maag had agreed to serve as Executive Chairman of the company's Board of Directors to facilitate an orderly transition. Now that this transition is complete, Dr. Maag will step down as Executive Chairman but will continue to serve the ..." |
|
| 10/28/2021 |
8-K
| Quarterly results |
| 09/15/2021 |
8-K
| Quarterly results |
| 07/29/2021 |
8-K
| Quarterly results |
| 07/20/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/01/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/17/2021 |
8-K
| Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea... |
| 06/03/2021 |
8-K
| Quarterly results |
| 05/05/2021 |
8-K
| Quarterly results |
| 03/11/2021 |
8-K
| Quarterly results |
| 02/24/2021 |
8-K
| Quarterly results |
| 01/21/2021 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Underwriting Agreement, by and among CareDx, Inc. and Goldman Sachs & Co. LLC and Jefferies LLC as the representatives of the underwriters named therein",
"Opinion of Paul Hastings LLP",
"CareDx Announces Pricing of Public Offering of Common Stock SOUTH SAN FRANCISCO, Calif., January 20, 2021 — CareDx, Inc. , a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the pricing of an underwritten public offering of 1,923,077 shares of its common stock at a public offering price of $91.00 per share. The gross proceeds to CareDx from this offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $175,000,007. In addition, CareDx has granted the underwriters a 30 day option to purchase up to 288,461 additional shares of its common stock offered in the public offering on the..." |
|
| 01/11/2021 |
8-K
| Quarterly results |
| 12/10/2020 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
|
|
|